After decades of limited success in the treatment of castration-resistant prostate cancer
(CRPC), five novel therapeutics were granted Food and Drug Administration regulatory …

Suppression of gonadal androgens by medical or surgical castration remains the mainstay
of treatment for patients with advanced prostate cancer. However, the response to treatment …

The discovery of androgen dependence in prostate cancer in 1941 by Huggins and
colleagues has remained the backbone for the treatment of this disease. However, although …

What's known on the subject? and What does the study add? Castration resistance has
been appreciated for decades, and several mechanisms theorising on this effect have been …

Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …

The androgen signaling axis has been the main therapeutic target in the management of
advanced prostate cancer for several decades. Over the past years, significant advances …

Prostate cancer is the most common cancer and the second leading cause of death from
cancer in males in most Western countries. Prostate cancer has an exquisite sensitivity to …

Persistent androgen receptor (AR) signaling despite low levels of serum androgens has
been identified as a critical target for drug discovery in castration-resistant prostate cancer …

Introduction The gold standard of medical therapy for advanced prostate cancer is based on
the use of androgen-receptor inhibitors and taxane-based chemotherapy. Several new …

Prostate cancer is a heterogeneous disease where the previous concept of “hormone
resistance” has been changed by a new generation of hormonal therapies that have proven …